Relaxometric studies of gadolinium-functionalized perfluorocarbon nanoparticles for MR imaging

Contrast Media and Molecular Imaging

Volumn 9, Issue 1, 2014, Pages 83-91

  de Vries, Anke ^a   Moonen, Rik ^a   Yildirim, Muhammed ^b   Langereis, Sander ^b   Lamerichs, Rolf ^b   Pikkemaat, Jeroen A ^b   Baroni, Simona ^c   Terreno, Enzo ^c   Nicolay, Klaas ^a   Strijkers, Gustav J ^a   Grüll, Holger ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c Dipartimento di Chimica IFM   (Italy)

Author keywords

19fluorine; Gadolinium; MRI; Nanoparticles; Perfluorocarbon; Relaxometry

Indexed keywords

FLUORINE; FLUOROCARBON; GADOLINIUM; LANTHANIDE; NANOPARTICLE; PENTETIC ACID; PROTON; WATER;

AQUEOUS SOLUTION; ARTICLE; CELL TRACKING; CONTROLLED STUDY; DISPERSION; EMULSION; HUMAN; HUMAN TISSUE; MEASUREMENT; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRENGTH;

19FLUORINE; GADOLINIUM; MRI; NANOPARTICLES; PERFLUOROCARBON; RELAXOMETRY;

CELL TRACKING; CONTRAST MEDIA; EMULSIONS; FLUOROCARBONS; GADOLINIUM; HUMANS; LIPIDS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; PROTONS;

EID: 84893124238     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1541     Document Type: Article

References (31)

1. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, et al. Quantitative 'magnetic resonance immunohistochemistry' with ligand-targeted (19)F nanoparticles. Magn Reson Med 2004; 52: 1255-1262; doi: 10.1002/mrm.20287
2. Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson 2008; 10: 43.
3. Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, et al. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine 2009; 5: 359-367.
4. Ruiz-Cabello J, Walczak P, Kedziorek DA, Chacko VP, Schmieder AH, Wickline SA, et al. In vivo 'hot spot' MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med 2008; 60: 1506-1511.
5. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007; 58: 725-734.
6. Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific T cells using 19F MRI. Magn Reson Med 2009; 62: 747-753.
7. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1: 492-501.
8. Mason RP, Antich PP, Babcock EE, Gerberich JL, Nunnally RL. Perfluorocarbon imaging in vivo: a 19F MRI study in tumor-bearing mice. Magn Reson Imag 1989; 7: 475-485.
9. Kadayakkara DK, Janjic JM, Pusateri LK, Young WB, Ahrens ET. In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI. Magn Reson Med 2010; 64: 1252-1259.
10. Ratner AV, Quay S, Muller HH, Simpson BB, Hurd R, Young SW. 19F relaxation rate enhancement and frequency shift with Gd-DTPA. Invest Radiol 1989; 24: 224-227.
11. Chalmers KH, De Luca E, Hogg NH, Kenwright AM, Kuprov I, Parker D, et al. Design principles and theory of paramagnetic fluorine-labelled lanthanide complexes as probes for (19)F magnetic resonance: a proof-of-concept study. Chemistry 2010; 16: 134-148.
12. Neubauer AM, Myerson J, Caruthers SD, Hockett FD, Winter PM, Chen J, et al. Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med 2008; 60: 1066-1072.
13. Hu L, Zhang L, Chen J, Lanza GM, Wickline SA. Diffusional mechanisms augment the fluorine MR relaxation in paramagnetic perfluorocarbon nanoparticles that provides a 'relaxation switch' for detecting cellular endosomal activation. J Magn Reson Imag 2011; 34: 653-661.
14. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242: 647-649.
15. Stratta P, Canavese C, Aime S. Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. Curr Med Chem 2008; 15: 1229-1235.
16. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imag 2009; 30: 1259-1267.
17. Winter PM, Athey P, Kiefer G, Gulyas G, Frank K, Fuhrhop R, et al. Improved paramagnetic chelate for molecular imaging with MRI. J Magn Magn Mater 2005; 293: 540-545.
18. Hak S, Sanders HM, Agrawal P, Langereis S, Grull H, Keizer HM, et al. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm 2009; 72: 397-404.
19. Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496.
20. Henoumont C, Laurent S, Vander Elst L. How to perform accurate and reliable measurements of longitudinal and transverse relaxation times of MRI contrast media in aqueous solutions. Contrast Media Mol Imag 2009; 4: 312-321.
21. +++. J Chem Phys 1959; 31: 365
22. Freed JH. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T1 processes. J Chem Phys 1978; 68: 4034-4037
23. Woessner DE. Nuclear spin relaxation in ellipsoids undergoing rotational brownian motion. J Chem Phys 1962; 37(3): 647-654
24. Troughton JS, Greenfield MT, Greenwood JM, Dumas S, Wiethoff AJ, Wang J, et al. Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem 2004; 43: 6313-6323.
25. Zhang Z, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed Engl 2005; 44: 6766-6769.
26. Strijkers GJ, Mulder WJ, van Heeswijk RB, Frederik PM, Bomans P, Magusin PC, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 2005; 18: 186-192.
27. Kielar F, Tei L, Terreno E, Botta M. Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the GdIII chelates. J Am Chem Soc 2010; 132: 7836-7837.
28. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-2352.
29. Jacques V, Dumas S, Sun WC, Troughton JS, Greenfield MT, Caravan P. High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol 2010; 45: 613-624.
30. Shukla HP, Mason RP, Woessner DE, Antich PP. A comparison of three commercial perfluorocarbon emulsions as high-field 19F NMR probes of oxygen tension and temperature. J Magn Reson Ser B 1995; 106: 131-141.
31. Koenig SH, Brown RD 3rd. Relaxation of solvent protons by paramagnetic ions and its dependence on magnetic field and chemical environment: implications for NMR imaging. Magn Reson Med 1984; 1: 478-495.